29 related articles for article (PubMed ID: 15004490)
1. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA).
Kountourakis P; Psyrri A; Scorilas A; Camp R; Markakis S; Kowalski D; Diamandis EP; Dimopoulos MA
Cancer Sci; 2008 Nov; 99(11):2224-9. PubMed ID: 18957059
[TBL] [Abstract][Full Text] [Related]
2. Correction: The HK5 and HK6 cytokinin receptors mediate diverse developmental pathways in rice.
Burr CA; Sun J; Yamburenko MV; Willoughby A; Hodgens C; Boeshore SL; Elmore A; Atkinson J; Nimchuk ZL; Bishopp A; Schaller GE; Kieber JJ
Development; 2023 Aug; 150(15):. PubMed ID: 37526652
[No Abstract] [Full Text] [Related]
3. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.
Kurlender L; Yousef GM; Memari N; Robb JD; Michael IP; Borgoño C; Katsaros D; Stephan C; Jung K; Diamandis EP
Tumour Biol; 2004; 25(3):149-56. PubMed ID: 15361712
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
[TBL] [Abstract][Full Text] [Related]
5. Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.
Dorn J; Yassouridis A; Walch A; Diamandis EP; Schmitt M; Kiechle M; Wang P; Drecoll E; Schmalfeldt B; Loessner D; Kotzsch M; Magdolen V
Am J Cancer Res; 2016; 6(1):61-70. PubMed ID: 27073723
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system.
Tan Y; Tang T; Xu H; Zhu C; Cunningham BT
Biosens Bioelectron; 2015 Nov; 73():32-40. PubMed ID: 26043313
[TBL] [Abstract][Full Text] [Related]
7. OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery.
Dorn J; Bronger H; Kates R; Slotta-Huspenina J; Schmalfeldt B; Kiechle M; Diamandis EP; Soosaipillai A; Schmitt M; Harbeck N
Oncol Lett; 2015 Jan; 9(1):418-424. PubMed ID: 25436002
[TBL] [Abstract][Full Text] [Related]
8. Nanostructured optical photonic crystal biosensor for HIV viral load measurement.
Shafiee H; Lidstone EA; Jahangir M; Inci F; Hanhauser E; Henrich TJ; Kuritzkes DR; Cunningham BT; Demirci U
Sci Rep; 2014 Feb; 4():4116. PubMed ID: 24576941
[TBL] [Abstract][Full Text] [Related]
9. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.
Schmitt M; Magdolen V; Yang F; Kiechle M; Bayani J; Yousef GM; Scorilas A; Diamandis EP; Dorn J
Radiol Oncol; 2013; 47(4):319-29. PubMed ID: 24294176
[TBL] [Abstract][Full Text] [Related]
10. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.
Shahinian H; Loessner D; Biniossek ML; Kizhakkedathu JN; Clements JA; Magdolen V; Schilling O
Mol Oncol; 2014 Feb; 8(1):68-82. PubMed ID: 24120346
[TBL] [Abstract][Full Text] [Related]
11. Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.
Pépin D; Shao ZQ; Huppé G; Wakefield A; Chu CW; Sharif Z; Vanderhyden BC
PLoS One; 2011; 6(11):e26075. PubMed ID: 22102857
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.
Avgeris M; Papachristopoulou G; Polychronis A; Scorilas A
Clin Proteomics; 2011 May; 8(1):5. PubMed ID: 21906360
[TBL] [Abstract][Full Text] [Related]
13. Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
Fritzsche F; Gansukh T; Borgoño CA; Burkhardt M; Pahl S; Mayordomo E; Winzer KJ; Weichert W; Denkert C; Jung K; Stephan C; Dietel M; Diamandis EP; Dahl E; Kristiansen G
Br J Cancer; 2006 Feb; 94(4):540-7. PubMed ID: 16434994
[TBL] [Abstract][Full Text] [Related]
14. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Diamandis EP; Borgoño CA; Scorilas A; Yousef GM; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M
Tumour Biol; 2003; 24(6):299-309. PubMed ID: 15004490
[TBL] [Abstract][Full Text] [Related]
15. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols.
Shan SJ; Scorilas A; Katsaros D; Rigault de la Longrais I; Massobrio M; Diamandis EP
Clin Chem; 2006 Oct; 52(10):1879-86. PubMed ID: 16916986
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091
[TBL] [Abstract][Full Text] [Related]
17. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D
Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660
[TBL] [Abstract][Full Text] [Related]
18. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.
Diamandis EP; Borgoño CA; Scorilas A; Harbeck N; Dorn J; Schmitt M
Clin Biochem; 2004 Sep; 37(9):823-9. PubMed ID: 15329323
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer.
Riedel M; Bronger H; Magdolen V; Dreyer T
Expert Rev Mol Diagn; 2021 Jun; 21(6):535-545. PubMed ID: 33947310
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
